Abraham Scaria

Abraham Scaria

Company: Beacon Therapeutics

Job title: CSO

Seminars:

Panel Discussion: Novel Modalities & Next Generation of Complement Inhibitors 4:00 pm

Where is the next step for complement inhibitors? Examine the past, present, and future, of complement inhibitors for autoimmune conditions and they may fit alongside existing therapiesRead more

day: End of Conference Day Two

Upstream vs. Downstream Targeting in GA & AMD 1:30 pm

Discussing the advantages and disadvantages of different complement targets through an ophthalmology lens Delivering complement inhibitors to the eye: topical, intravitreal, or systemic? Future considerations for combination therapies to target multiple complement components in the eyeRead more

day: Conference Day Two

Panel Discussion: Dysregulation Insights: An Overview of the Complement System in Health & Human Disease 8:30 am

Unravelling the 3 complement pathways and potential intervention points Understanding core processes in healthy inflammatory response in comparison to pathophysiology of autoimmune conditions Discussing the optimal modalities for delivering complement mediated drugs: small molecules, antibodies, and gene therapiesRead more

day: Conference Day One

Preclinical Updates for Complement Regulators Using Gene Therapies 4:00 pm

The benefits of using gene therapies to target complement mediated diseases Using a localised approach to target the eye and mitigate toxicity Updates in targeting Geographic Atrophy/Dry AMDRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.